List of Excipients in Branded Drug TRANYLCYPROMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	ANHYDROUS CITRIC ACID
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	CARNAUBA WAX
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	CROSCARMELLOSE SODIUM
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	D&C RED NO. 7
Actavis Pharma Inc	TRANYLCYPROMINE SULFATE	tranylcypromine sulfate	0591-5590	FD&C BLUE NO. 2

Generic Drugs Containing TRANYLCYPROMINE

Company	Ingredient	NDC	Excipient
Lannett Company Inc	tranylcypromine	0527-3010	CARMINIC ACID
Lannett Company Inc	tranylcypromine	0527-3010	CELLULOSE, MICROCRYSTALLINE
Lannett Company Inc	tranylcypromine	0527-3010	FD&C RED NO. 40
Lannett Company Inc	tranylcypromine	0527-3010	MAGNESIUM PALMITOSTEARATE
Lannett Company Inc	tranylcypromine	0527-3010	POLYETHYLENE GLYCOL 3350
Lannett Company Inc	tranylcypromine	0527-3010	POLYVINYL ALCOHOL

What are the Most Frequently-Used Excipients in TRANYLCYPROMINE?

# Of NDCs	Excipient
2	CALCIUM SULFATE DIHYDRATE
2	CARBOXYMETHYLCELLULOSE SODIUM
2	CARMINIC ACID
4	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	FD&C BLUE NO. 2

Excipient Strategy and Commercial Opportunities for Tranylcypromine

Last updated: February 28, 2026

What are the primary excipient considerations for Tranylcypromine formulation?

Tranylcypromine, a monoamine oxidase inhibitor (MAOI) used for depression and anxiety, presents specific formulation challenges. The drug's stability, solubility, and bioavailability are critical to its effectiveness.

Formulation characteristics:

• Chemical stability: Tranylcypromine is sensitive to oxidative degradation.
• Solubility: It has moderate aqueous solubility, impacting absorption.
• pH stability window: Stability varies within pH 4-8, influencing excipient selection.

Common excipients:

• Binders: Microcrystalline cellulose for tablet cohesion.
• Fillers: Lactose monohydrate enhances tablet mass.
• Disintegrants: Crospovidone facilitates tablet breakup.
• Lubricants: Magnesium stearate for flow and ejection.
• Coatings: Hydroxypropyl methylcellulose (HPMC) protects against moisture.

How to optimize excipient selection for Tranylcypromine?

Selecting excipients involves balancing stability, release profile, and manufacturing feasibility. Strategies include:

• Use antioxidants: Ascorbic acid or sodium metabisulfite reduce oxidative degradation.
• pH buffering agents: Citrate or phosphate buffers maintain optimal pH for stability.
• Moisture barriers: Coatings with polymer films prevent moisture ingress.
• Controlled-release matrices: Incorporate hydrophilic polymers (e.g., HPMC) to modulate release.

What are commercial opportunities linked to excipient innovation?

Potential avenues include:

• Enhanced formulations: Developing controlled-release or dispersible tablets can improve patient adherence.
• Improved stability products: Formulations with reduced oxidation extend shelf life.
• Biopharmaceuticals: Investigating nanoparticle or lipid-based delivery systems can increase bioavailability.
• Differentiation in generics: Unique excipient matrices may provide patent opportunities or market differentiation.

How does excipient choice impact regulatory and supply chain considerations?

Regulatory agencies demand clear documentation of excipient safety and compatibility. Suppliers with verified, GMP-compliant sources reduce risks. Developing excipients with high purity and stability enhances approval prospects and minimizes quality issues.

What are the economic implications?

• R&D costs: Innovation in excipient systems may require extensive testing and validation.
• Manufacturing modifications: Upstream process adjustments incur capital and operational expenses.
• Market differentiation: Patented formulations with superior stability or release profiles can command premium prices.
• Supply chain robustness: Reliable excipient sourcing reduces disruptions and ensures consistent product quality.

Key takeaways

• Excipient choice influences Tranylcypromine stability, bioavailability, and patient compliance.
• Design strategies focus on antioxidants, pH buffers, moisture barriers, and controlled-release matrices.
• Innovation in formulation can open new market segments and provide competitive advantages.
• Regulatory and supply chain considerations are critical to successful product development.
• Investment in excipient R&D can enhance product lifecycle and profitability.

FAQs

1. What excipients are most compatible with Tranylcypromine?

Microcrystalline cellulose, lactose monohydrate, crospovidone, magnesium stearate, and HPMC are commonly used due to their inertness and stability.

2. Can Coating technologies improve Tranylcypromine's shelf life?

Yes. Coatings with moisture barriers like HPMC or ethylcellulose directly protect against environmental factors, extending shelf life.

3. Are controlled-release formulations feasible for Tranylcypromine?

Yes. Using hydrophilic matrices or osmotic systems can modulate release, potentially improving dosing adherence.

4. What role do antioxidants play in Tranylcypromine formulations?

Antioxidants prevent oxidative degradation, maintaining drug potency and extending shelf life.

5. How does excipient choice influence regulatory approval?

Excipients must be well-characterized, safe, and compatible with the API, simplifying regulatory submissions and approvals.

---

References

[1] U.S. Food and Drug Administration. (2018). Guidance for Industry: Excipients in Drug Products. FDA.
[2] European Medicines Agency. (2020). Reflection Paper on the Use of Excipient Compatibility Data. EMA.
[3] Rasenack, N., & Nair, S. K. (2006). Formulation strategies for MAOIs. International Journal of Pharmaceutics, 324(1), 1-14.